Patent intelligence · US
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
Substituted n-propylamine fused heterocyclic mescaline derivatives
Patent details — US 12358885
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 15, 2025
- Expiration
- Jul 10, 2045
- Applicant
- Enveric Biosciences Canada Inc.
- Claims
- 12
- CPC classes
- A61P, A61P25/00
Quick answer
US 12358885 (Substituted n-propylamine fused heterocyclic mescaline derivatives) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enveric Biosciences Canada Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61P, A61P25/00
More from Enveric Biosciences Canada Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428408
Fused heterocyclic mescaline derivatives
granted -
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133856
Multi-substituent psilocybin derivatives and methods of using
granted
Frequently asked questions
What is US patent 12358885?
US 12358885 (Substituted n-propylamine fused heterocyclic mescaline derivatives) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12358885?
Enveric Biosciences Canada Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 12358885 expire?
Our index shows an expiration date of Jul 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.